th
La Cristalera, Miraflores de la Sierra, Madrid,
November 5-6th, 2013
SpHPP Council, La Cristalera, Nov 2013

AIMS
• Chromosome 16 annotation.
• Selection of 3 cell lines based on published transcriptomic profiles for maximum chromosome 16 coverage
• Transcriptomic analysis of the selected cell lines.
• Shotgun proteomic analysis of the selected cell lines.
• Development of SRM methods for 200 proteins/year.
• Expression of missing proteins and development of SRM methods.
32 research units organized in 5 WG:
WG1. Protein expression and purification. Peptides.
WG2. Development of quantitative S/MRM assays.
WG3. Shotgun proteomics. Molecular profiles and PTMs.
WG4. Bioinformatics
WG5. Biology and disease. Neurodegenerative, cardiovascular, infectious, cancer, obesity,
Rheumatic disorders.

WG1. Composition
WG 1 .-Protein Expression,
Peptide Standard & Micro
Array Team
RU1a
(Protein Micro Array and
Protein Expression Team)
Dr. Manuel Fuentes
CIC/IBMCC
(USAL/CSIC),
Salamanca
Scientific
Researchers:
M. González
N. Dasilva
P. Díez
M. Pérez de Andrés
RU1b
(Protein Expression
Team 2)
Dr. Concha Gil
UCM-PCM,
Madrid
RU1c
(Peptide Standard Team)
Dr. Juan P Albar
CNB-CSIC,
ProteoRed, Madrid
RU1d
(Peptide
Standard Team)
Dr. Eliandre
Oliveira
PCB
Barcelona
RU1e
(Bioinformatics,PTM and cell lines)
Dr. Félix Elortza
CIC-BioGUNE
Bilbao
Scientific
Researchers:
M. L. Hernáez
F. Clemente
Scientific
Researchers:
M. Lombardía

WG1. Unknown protein definition
Missing proteins neXtProt: Organizing Protein Knowledge in the Context of Human Proteome Projects
J. Proteome Res. 2013, 12, 293−298
Pascale Gaudet,† Ghislaine Argoud-Puy,† Isabelle Cusin,† Paula Duek,† Olivier Evalet,† Alain Gateau,† Anne Gleizes,† Mario Pereira,†
Monique Zahn-Zabal,† Catherine Zwahlen,† Amos Bairoch,†,‡ and Lydie Lane*,†,‡ †
CALIPHO group, SIB-Swiss Institute of Bioinformatics, ‡Department of Human Protein Sciences, Faculty of Medicine, University of
Geneva, CMU-1, rue Michel Servet 1211 Geneva 4, Switzerland neXtProt Extends the Coverage of Identified Proteins in the Human Proteome
The primary targets of the C-HPP are the so-called “missing proteins” that have not yet been identified by mass spectrometry nor detected by antibodies. An important aspect of the C-HPP work is to define which proteins have already been characterized, to focus on those that have yet to be detected. To help C-HPP in this task, neXtProt captures evidence for the existence of each protein based on criteria established by
UniProtKB/Swiss-Prot in 2007. Five levels of evidence have been defined: (1) evidence at protein level (e.g., identification by mass spectrometry, detection by antibodies, sequence by Edman degradation, or tridimensional structure resolved), (2) evidence at transcript level (e.g., ESTs or full length mRNA), (3) inferred by homology
(strong sequence similarity to known proteins in related species), (4) predicted and (5) uncertain (e.g., dubious sequences that are likely the products of erroneous translations of pseudogenes)

1071
1216
1216
638
3844
Uncertain
Awaiting experimental validation
Validated at protein level AND
PeptideAtlas info
Validated at protein level AND other proteomic info
Validated at protein level AND no proteomics info
13359

626 HPA antibodies for Chr16 proteins, 95 for missing
2360 genes
840 protein coding genes
143 missing proteins
Protein expression vectors for 64 Chr16 missing proteins neXtProt v2013-10-10
ENSEMBL
UniProtKB v 2013_09
HPA v11 v73
120 OMIM hits
Obesity
Neurodegenerative diseases
Cancer
Shotgun
Proteomic analysis
Coverage of 73% gene products in
Lymphoid cells
Epitelial cells
Fibroblasts
Transcriptomic analysis
Protein profile Data integration Gene expression profile
Global and cell type specific outcomes
Correlation proteome/transcriptome
Proteome coverage and chromosome distribution
Chr16 proteome coverage

WG1. Activities
1. Bioinformatic analysis .
Update the missing proteins data according to neXtProt.
Definition of tissues and cell lines for biological validation and subcellular localization.
2 .
Protein expression.
* Clone isolation. Gene sequencing.
* Expression of proteins in a free cell system.
* Purification of expressed proteins.
3 . Development of SRM methods for expressed proteins .
4.
SRM assays in biological matrices (proteomes or subproteomes of different tissues or cell lines).
5.
Synthesize the appropriate peptides for developing quantitative MRM methods.

NeXtProt DATA
21
22
X
Y
MT unknown
18
19
20
14
15
16
17 chromosome
1
2
3
4
5
6
11
12
13
7
8
9
10
551
254
464
826
46
14
40
328
626
610
830
1165
277
1425 entry count
2061
1238
1076
763
867
1106
944
701
821
762
1319
1031
Description: Chromosome 16 report
Name: nextprot_chromosome_16
Release: 2013-09-26
656
941
226
1009
435
165
355
604
22
13
12
590
925
841
264
502
451 protein level
(PE1)
1589
1020
871
614
691
898
700
549
612
136
185
40
364
101
57
82
174
16
0
20
147
323
164
46
96
107 transcript level
(PE2)
385
186
174
109
155
164
179
97
152
0
4
4
6
7
3
11
0
4
10
0
2
7
8
3
24
5 homology
(PE3)
29
3
8
7
10
7
8
18
7
14
28
21
31
26
7
37
32
8
1
3
10
18
41
19
40
19 uncertain
(PE5)
49
20
30
52
39
43
20
20
10
1
0
2
1
4
1
6
0
1
6
0
6
3
3
3
7
2 predicted
(PE4)
9
9
6
7
6
6
3
2
4 awaiting protein validation (P2+P3+P4)
423
198
185
129
166
178
192
113
166
143
198
44
379
102
61
88
190
16
0
25
153
354
171
54
106
118

WG1. Unkown proteins clonning workflow
DNA sequencing
Plasmid isolation
Bacterial selection

WG1. Unkown proteins cloning
Chromosome 16 143 Unkown proteins
(260 before)
Cloned in pANT7_cGST
Digest with restriction enzymes
WG1
28 new proteins
Sequencing
Mass spectrometry
(MRM)
Expression (IVTT) and purification (GST)

WG1. Unkown proteins expression
List Price 1200 IVTT kit
230 Agarose beads
Sample price: 40 euros

WG1. Unkown proteins analysis workflow I
Expressed protein digestion Skyline peptide/transition selection
MRM assay

WG1. Unkown proteins analysis workflow III
MRM data checking and MSMS spectra validation

Uniprot
Accesion number
Q8WV35
O60359
Q8TEW6
Q8IUW3
Q9HBE5
Q8WTQ4
A8K8V0
Q6PII5
Q96H86
Q96A59
O95976
Q9NZS9
Q8NEV9
Q6UXU4
Q6PL45
Q9NWW0
Q8N635
Q96B96
Q8TDN1
Q8IYM1
Q8IZF4
P17023
O75324
Q9NXF8
Q8TAZ6
Q8TB05
Q9BTX3
Q8WVE7
WG1. Unkown proteins results (11 missing protein from 28 expressed protein)
Protein
LRRC29 Leucine-rich repeat-containing protein 29
CACNG3 Voltage-dependent calcium channel gamma-3 subunit
DOK4 Docking protein 4
SPATA2L Spermatogenesis-associated protein 2-like protein
IL21R Interleukin-21 receptor
C16ORF78 Uncharacterized protein C16orf78
ZNF785 Zinc finger protein 785
HAGHL Hydroxyacylglutathione hydrolase-like protein
ZNF764 Zinc finger protein 764
MARVELD3 MARVEL domain-containing protein 3
IGSF6 Immunoglobulin superfamily member 6
BFAR Bifunctional apoptosis regulator
IL27 Interleukin-27 subunit alpha
GSG1L Germ cell-specific gene 1-like protein
C16ORF79 BRICHOS domain-containing protein 5
HCFC1R1 Host cell factor C1 regulator 1
C16ORF73 Meiosis-specific with OB domain-containing protein
TMEM159 Promethin
KCNG4 Potassium voltage-gated channel subfamily G member 4
SEP12 Septin-12
GPR114 Probable G-protein coupled receptor 114
ZNF19 Zinc finger protein 19
SNN Stannin
ZDHC7 Palmitoyltransferase ZDHHC7
CKLFSF2 CKLF-like MARVEL transmembrane domain-containing protein 2
FAM100A UBA-like domain-containing protein 1
TMEM208 Transmembrane protein 208
TMEM170A Transmembrane protein 170A
Selected
peptides
Detected peptides
11
15
3
7
14
3
11
15
3
6
6
1
17
12
7
7
7
10
12
6
9
9
12
11
9
12
10
10
2
2
3
3
3
3
4
3
1
1
2
1
5
5
6
6
4
6
6
7
6
8
8
7
9
9
9
9
Identified peptides
1
2
1
0
2
2
1
2
0
0
1
1
5
0
2
1
2
6
3
6
6
5
2
7
8
6
9
8
28 Proteins with selected peptides ( Peptides that matched the specifications to be candidate to use it for quantitation)
22 Proteins with at least three detected peptides in the MRM experiment
24 Proteins with identified peptides by MASCOT in MIDAS experiment.

WG1. Location of unkown proteins
Protein
LRRC29 Leucine-rich repeat-containing protein 29
CACNG3 Voltage-dependent calcium channel gamma-3 subunit
DOK4 Docking protein 4
SPATA2L Spermatogenesis-associated protein 2-like protein
IL21R Interleukin-21 receptor
C16ORF78 Uncharacterized protein C16orf78
ZNF785 Zinc finger protein 785
HAGHL Hydroxyacylglutathione hydrolase-like protein
ZNF764 Zinc finger protein 764
MARVELD3 MARVEL domain-containing protein 3
IGSF6 Immunoglobulin superfamily member 6
BFAR Bifunctional apoptosis regulator
IL27 Interleukin-27 subunit alpha
GSG1L Germ cell-specific gene 1-like protein
C16ORF79 BRICHOS domain-containing protein 5
HCFC1R1 Host cell factor C1 regulator 1
C16ORF73 Meiosis-specific with OB domain-containing protein
TMEM159 Promethin
KCNG4 Potassium voltage-gated channel subfamily G member 4
SEP12 Septin-12
GPR114 Probable G-protein coupled receptor 114
ZNF19 Zinc finger protein 19
SNN Stannin
ZDHC7 Palmitoyltransferase ZDHHC7
CKLFSF2 CKLF-like MARVEL transmembrane domain-containing protein 2
FAM100A UBA-like domain-containing protein 1
TMEM208 Transmembrane protein 208
TMEM170A Transmembrane protein 170A
Location
Nucleus
MB
MB
Nucleus, mitochondria
MB
Citoplasmic
Nucleus
Expression
Expressed in heart, kidney, liver, lung and pancreas
Widely expressed. High expression in skeletal muscle, heart, kidney and liver.
widely expressed
Selectively expressed in lymphoid tissues. Most highly expressed in thymus and spleen.
Nucleus
MB
MB
Endoplasmic reticulum
Secreted
MB
MB
MB
MB
Expressed in peripheral blood lymphocytes, spleen and lymph node, with low levels in thymus, bone marrow and fetal liver
Expressed highly in brain, moderately in small intestine, weakly in testes and only faintly in liver and skeletal muscle
Prostate, pancreas, salivary glands
MB
MB
Expressed at high levels in the heart and skeletal muscle. Expressed at low levels in kidney, small intestine, lung and liver.
Highly expressed in brain, and at lower levels in liver, small intestine and colon.
cytoskeleton
MB
Nucleus
Mitochondrion outer
Widely expressed membrane
Golgi
MB Highly expressed in testis
Endoplasmic reticulum membrane
MB

WG1. Unknown proteins
Protein
LRRC29 Leucine-rich repeat-containing protein 29
CACNG3 Voltage-dependent calcium channel gamma-3 subunit
DOK4 Docking protein 4
SPATA2L Spermatogenesis-associated protein 2-like protein
IL21R Interleukin-21 receptor
C16ORF78 Uncharacterized protein C16orf78
ZNF785 Zinc finger protein 785
HAGHL Hydroxyacylglutathione hydrolase-like protein
ZNF764 Zinc finger protein 764
MARVELD3 MARVEL domain-containing protein 3
IGSF6 Immunoglobulin superfamily member 6
BFAR Bifunctional apoptosis regulator
IL27 Interleukin-27 subunit alpha
GSG1L Germ cell-specific gene 1-like protein
C16ORF79 BRICHOS domain-containing protein 5
HCFC1R1 Host cell factor C1 regulator 1
C16ORF73 Meiosis-specific with OB domain-containing protein
TMEM159 Promethin
KCNG4 Potassium voltage-gated channel subfamily G member 4
SEP12 Septin-12
GPR114 Probable G-protein coupled receptor 114
ZNF19 Zinc finger protein 19
SNN Stannin
ZDHC7 Palmitoyltransferase ZDHHC7
CKLFSF2 CKLF-like MARVEL transmembrane domain-containing protein 2
FAM100A UBA-like domain-containing protein 1
TMEM208 Transmembrane protein 208
TMEM170A Transmembrane protein 170A
YES
No
YES
No
YES
No
YES
YES
No
No
No
No
No
No
No
No
YES
Missing protein
YES
YES
No
No
No
YES
YES
Expression
Proteomics and expression
Expression
Proteomics
Proteomics and expression
Proteomics and expression
Proteomics and expression
Proteomics and expression
Expression
Experimental
Proteomics and expression
Expression
3D
Experimental
YES
No
No
No
Proteomics
Proteomics and expression
Proteomics
Evidence
PA
Two proteotipic peptides. WB, PA
WB, PA
One proteotipic peptide
One proteotipic peptide. WB, PA
Three proteotipic peptides. PA
One proteotipic peptide. PA
Four proteotipic peptides. WB
Others
Three proteotipic peptides. WB
IF, WB, PA
One proteotipic peptide
One proteotipic peptide. WB, PA
One proteotipic peptide
PA : protein array, WB : western blot, IF : immunofluorescency

Working plan for Missing Proteins WP 2013-14
• Definition of the Chr16 missing proteins group. As indicated in neXtProt.
• Expression of 60 proteins/year.
• Development of SRM assays and test in biological matrices.
• Peptide synthesis for quantitative SRM methods.
• NAPPA and antibody arrays for B/D.
October 2013
Nov 2013
Dec 2013
Jan 2014
Feb2014
March 2014
April2014
May 2014
• Definition of the missing group according to neXtProt. Available NAPPA and antibody resources.
•
Definition of tissue and cell lines for biological validation.
•
Validation of SRM assays for previously synthetised proteins in biological matrices.
• Vector production and optimization (??proteins)
•
Synthesis of peptides for missing proteins with no expression vector.
• Development of SRM methods for new missing proteins using the recombinant form or peptides
• Validation in biological matrices.
•
List of potential biomarkers from B/D groups
• Validation of SRM methods in three independent labs.
•
Design of arrays for B/D WP. Biomarkers.
Dec 2014
Groups
CNB
UCM-PCM
PCB
CIC-BIOGUNE
CIC-USAL
Topics for discussion
• Expression only for missing proteins?
• For validation, select the tissue/cell line with higher gene expression.
• Recombinant protein purification?
• Criteria to select peptides for synthesis.
• Contact Josua Labaer if clones are not available in Salamanca.
Other groups might also participate in defining the best biological matrix and also in the interlaboratory validation process.

Working plan for Missing Proteins WP 2013-14
• Definition of the Chr16 missing proteins group. As indicated in neXtProt .
• Expression of 60 proteins/year
• Development of SRM assays
• Test in biological matrices.
• Peptide synthesis for quantitative SRM methods.
• Antibody and NAPPA arrays for B/D groups (2 year, 2015) (Proyectos Manuel
Fuentes, Francisco Blanco, Ignacio Casal , Concha Gil, ………….)
October 2013 • Definition of the missing group according to neXtProt.
Nov 2013
Dec 2013
Jan 2014
Feb2014
March 2014
April2014
• 28 expressed proteins (11 proteins still missing proteins)
• Definition of tissue and cell lines for biological validation (Colaboration with Banco Nacional de ADN, Banco líneas celulares)
•
• .
Validation of SRM assays for previously synthetised proteins in biological matrices (3 labs-
MRM group
• Synthesis of peptides for missing proteins with no expression vector
May 2014
• Expression of 53 missing proteins (if clones are available)
• Development of SRM methods for new missing proteins using the recombinant form or peptides
• Validation in biological matrices.
• List of potential biomarkers from B/D groups
Dec 2014

Working plan for Missing Proteins WP 2013-14
• Definition of the Chr16 missing proteins group. As indicated in neXtProt .
• Expression of 60 proteins/year
• Development of SRM assays
• Test in biological matrices.
• Peptide synthesis for quantitative SRM methods.
• Antibody and NAPPA arrays for B/D groups (2 year, 2015) (Proyectos Manuel
Fuentes, Francisco Blanco, Ignacio Casal , Concha Gil, ………….)
Groups
CNB
UCM-PCM
PCB
CIC-BIOGUNE
CIC-USAL
Topics for discussion
• Expression only for missing proteins ??
• For validation, select the tissue/cell line with higher gene expression.
• Recombinant protein purification?
• Criteria to select peptides for synthesis.
• Contact Josua Labaer if clones are not available in Salamanca (done)
Other groups might also participate in defining the best biological matrix and also in the interlaboratory validation process.

WG1. Unknown proteins peptides
Protein Nam e sp|Q96H86|ZN764_HUMAN sp|Q96H86|ZN764_HUMAN sp|Q96H86|ZN764_HUMAN sp|Q96H86|ZN764_HUMAN sp|Q96H86|ZN764_HUMAN sp|Q96H86|ZN764_HUMAN sp|Q96H86|ZN764_HUMAN sp|Q9BTX3|TM208_HUMAN sp|Q96B96|TM159_HUMAN sp|Q96B96|TM159_HUMAN sp|Q96B96|TM159_HUMAN sp|Q96B96|TM159_HUMAN sp|O75324|SNN_HUMAN sp|O75324|SNN_HUMAN sp|O75324|SNN_HUMAN sp|Q9HBE5|IL21R_HUMAN sp|Q9HBE5|IL21R_HUMAN sp|Q9HBE5|IL21R_HUMAN sp|Q9HBE5|IL21R_HUMAN sp|Q9HBE5|IL21R_HUMAN sp|Q9HBE5|IL21R_HUMAN sp|Q9HBE5|IL21R_HUMAN sp|Q9HBE5|IL21R_HUMAN sp|Q9NWW0|HPIP_HUMAN sp|Q9NWW0|HPIP_HUMAN sp|Q9NWW0|HPIP_HUMAN sp|Q9NWW0|HPIP_HUMAN
Peptide Sequence
AFAYPSDLR
VHSGETPFPCPDCGR
SALTSHLR
GRPSLCAHPPVPR
FSQSSALYQHR
GFGHASSLSK
VHSGETPFPCPDCGR
QIFEENR
LSLLIDSFQNNSK
DLQELQK
EEPQSISR
LSLLIDSFQNNSK
ISQSEDEESIVGDGETK
EPFLLVQYSAK
ISQSEDEESIVGDGETK
SVSLLPLEFR
DSSYELQVR
IWAVPSPER
GDPWAVSPR
LQYELQYR
LKPPLADGEDWAGGLPWGGR
FFMPLYK
SDYEDPAFYMLK
YPGSLIPEALR
SPCSELLLWR
MILQQPLQR
LEEEQEPLR sp|Q6PL45|BRID5_HUMAN sp|Q6PL45|BRID5_HUMAN sp|Q6PL45|BRID5_HUMAN sp|Q6PL45|BRID5_HUMAN sp|Q6PL45|BRID5_HUMAN sp|Q9NXF8|ZDHC7_HUMAN sp|Q9NXF8|ZDHC7_HUMAN sp|Q9NXF8|ZDHC7_HUMAN
TPIYWAR
LLVDTSK
MTLPSPHMPRPNQTILVDVAR
AEGESGPLWGK
LMEDSDR
SEKPTWER
EYMESLQLKPGEVIYK
DVEHHPLLAENDNYDSSSSSSSEADVADR
Protein Nam e sp|Q8TB05|F100A_HUMAN sp|Q8TB05|F100A_HUMAN sp|Q8WV35|LRC29_HUMAN sp|Q8WV35|LRC29_HUMAN sp|Q8WV35|LRC29_HUMAN sp|Q8WV35|LRC29_HUMAN sp|Q8WV35|LRC29_HUMAN sp|Q8WV35|LRC29_HUMAN sp|Q8WV35|LRC29_HUMAN sp|Q8WV35|LRC29_HUMAN sp|Q8WV35|LRC29_HUMAN sp|Q96A59|MALD3_HUMAN sp|Q96A59|MALD3_HUMAN sp|Q96A59|MALD3_HUMAN sp|Q96A59|MALD3_HUMAN sp|Q96A59|MALD3_HUMAN sp|Q96A59|MALD3_HUMAN sp|Q96A59|MALD3_HUMAN sp|Q8TEW6|DOK4_HUMAN sp|Q8TEW6|DOK4_HUMAN sp|Q8TEW6|DOK4_HUMAN sp|Q8TEW6|DOK4_HUMAN sp|Q8TEW6|DOK4_HUMAN sp|Q8TEW6|DOK4_HUMAN sp|Q8TEW6|DOK4_HUMAN sp|Q8TEW6|DOK4_HUMAN sp|Q8TEW6|DOK4_HUMAN sp|Q8IYM1|SEP12_HUMAN sp|Q8IYM1|SEP12_HUMAN sp|Q8IYM1|SEP12_HUMAN sp|Q8IYM1|SEP12_HUMAN sp|Q8IYM1|SEP12_HUMAN sp|Q8IYM1|SEP12_HUMAN sp|Q8NEV9|IL27A_HUMAN sp|Q8NEV9|IL27A_HUMAN sp|Q8NEV9|IL27A_HUMAN sp|Q8NEV9|IL27A_HUMAN sp|Q8NEV9|IL27A_HUMAN sp|Q8NEV9|IL27A_HUMAN sp|Q8NEV9|IL27A_HUMAN sp|Q8NEV9|IL27A_HUMAN
Peptide Sequence
HQVMINQFVLTAGCAADQAK
HQVMINQFVLTAGCAADQAK
VLQFLQLR
DACPEPQGPSLLTLR
LTDASLAK
GWAQAASSWPR
DACPEPQGPSLLTLR
ALQELDLTACSK
FQAQLPQVSCVQSR
QLSLSLLPELTDNGLVAVAR
SRPELEHQASGTK
GLTWDAAAPPGPAPWEAPEPPQPQR
EEVEYYQSEAEGLLECHK
AQQLDVQFYQLK
AQQLDVQFYQLK
AGEHGVWEKPR
AGEHGVWEKPR
YLPSTPRPGR
FTFEAGR
TLSVECLGSR
QAVAIIFTDDSAR
VTEISNVK
VHSATLAIAEQHK
QAVAIIFTDDSAR
LVSWPLCSLR
LNDISLGEPDLLAPGVQCEQTDR
LQITHENIYLWDIHNPR
TVNVVPVIAR
MGFEFNIMVVGQSGLGK
TVNVVPVIAR
LNESHLLPR
MGFEFNIMVVGQSGLGK
TVNVVPVIAR
ELLLLSK
EFTVSLHLAR
EFTVSLHLAR
AGHSVWPLGFPTLSPQP
GLLPGALGSALQGPAQVSWPQLLSTYR
FQVLAAGFNLPEEEEEEEEEEEEER
LLHSLELVLSR
LLHSLELVLSR

WG1. Unknown proteins peptides
Protein Nam e sp|O60359 CACNG3 sp|O60359 CACNG4 sp|O60359 CACNG5 sp|O60359 CACNG6 sp|O60359 CACNG7 sp|O60359 CACNG8 sp|O60359 CACNG9 sp|O60359 CACNG10 sp|O60359 CACNG11 sp|Q6UXU4|GSG1L_HUMAN sp|Q6UXU4|GSG1L_HUMAN sp|Q6UXU4|GSG1L_HUMAN sp|Q6UXU4|GSG1L_HUMAN sp|Q6UXU4|GSG1L_HUMAN sp|Q6UXU4|GSG1L_HUMAN sp|Q6UXU4|GSG1L_HUMAN sp|Q6UXU4|GSG1L_HUMAN sp|A8K8V0|ZN785_HUMAN sp|A8K8V0|ZN785_HUMAN sp|A8K8V0|ZN785_HUMAN sp|A8K8V0|ZN785_HUMAN sp|A8K8V0|ZN785_HUMAN sp|A8K8V0|ZN785_HUMAN sp|A8K8V0|ZN785_HUMAN sp|A8K8V0|ZN785_HUMAN sp|A8K8V0|ZN785_HUMAN
Peptide Sequence
ITMGTLLNSDR
IDHFPEDADYEQDTAEYLLR
GFHTIPSTDISMFTLSR
TCCLEGAFR
DHAFLQFHNSTPK
DLSPISK
DHAFLQFHNSTPK
NEEVMTHSGLWR
NEEVMTHSGLWR
SSAQEAPELNR
EEPTFIDPEAIK
VFEQGYR
DGSEEDFHLDCR
EEPTFIDPEAIK
HQPHMADSWPR
SSAQEAPELNR
DGSEEDFHLDCR
FTYPYLLAIHQR
NFSYPSLLASHQR
FAYTSLLAIHR
FTYSSLLLSHR
FAYTSLLAIHR
FTYSSLLLSHR
YLLQHQFIHTGEKPYPCPDCGR
HTGEKPYSCPDCSLR
AHTGEKPYACSDCK sp|Q8IUW3|SPA2L_HUMAN sp|Q8IUW3|SPA2L_HUMAN sp|Q8IUW3|SPA2L_HUMAN sp|Q8IUW3|SPA2L_HUMAN sp|Q8IUW3|SPA2L_HUMAN sp|Q8IUW3|SPA2L_HUMAN sp|Q8IUW3|SPA2L_HUMAN sp|Q8IUW3|SPA2L_HUMAN sp|Q8IUW3|SPA2L_HUMAN sp|Q8WTQ4|CP078_HUMAN sp|Q8WTQ4|CP078_HUMAN sp|Q8WTQ4|CP078_HUMAN sp|Q8WTQ4|CP078_HUMAN sp|Q8WTQ4|CP078_HUMAN sp|Q8WTQ4|CP078_HUMAN sp|Q8WTQ4|CP078_HUMAN sp|Q8WTQ4|CP078_HUMAN
GVLSDDLLLK
LAQDEEPPPLPPR
LAQDEEPPPLPPR
ASGDVASCVAWLQQR
TFSGGYVHVLK
ELSRPGDLATPESSAAASPR
ASGDVASCVAWLQQR
QLHAAHCAALPACRPGHSLR
AFELLELAAVHLYLLPWR
DAVDPESTQRPNPFR
SLYGVEQK
MLKPEEVLSCR
HLSMVPGSYIK
DAGMNVDIHPHMVEEDIDAK
MPDMAYER
QSIVLDPMLQEGTFNSQR
MSDLTCVLEWLER
Protein Nam e sp|O95976|IGSF6_HUMAN sp|O95976|IGSF6_HUMAN sp|O95976|IGSF6_HUMAN sp|O95976|IGSF6_HUMAN sp|O95976|IGSF6_HUMAN sp|O95976|IGSF6_HUMAN sp|Q9NZS9|BFAR_HUMAN sp|Q9NZS9|BFAR_HUMAN sp|Q9NZS9|BFAR_HUMAN sp|Q9NZS9|BFAR_HUMAN sp|Q9NZS9|BFAR_HUMAN sp|Q9NZS9|BFAR_HUMAN sp|Q9NZS9|BFAR_HUMAN sp|Q9NZS9|BFAR_HUMAN sp|Q9NZS9|BFAR_HUMAN sp|Q8N635|MEIOB_HUMAN sp|Q8N635|MEIOB_HUMAN sp|Q8N635|MEIOB_HUMAN sp|Q8N635|MEIOB_HUMAN sp|Q8N635|MEIOB_HUMAN sp|Q8TDN1|KCNG4_HUMAN sp|Q8TDN1|KCNG4_HUMAN sp|Q8TDN1|KCNG4_HUMAN sp|Q6PII5|HAGHL_HUMAN sp|Q6PII5|HAGHL_HUMAN sp|Q6PII5|HAGHL_HUMAN sp|Q6PII5|HAGHL_HUMAN sp|Q6PII5|HAGHL_HUMAN sp|Q6PII5|HAGHL_HUMAN sp|Q6PII5|HAGHL_HUMAN sp|Q8IZF4|GP114_HUMAN sp|Q8IZF4|GP114_HUMAN sp|Q8IZF4|GP114_HUMAN tr|Q5I2A4|Q5I2A4_HUMAN tr|Q5I2A4|Q5I2A4_HUMAN tr|Q5I2A4|Q5I2A4_HUMAN sp|Q8WVE7|T170A_HUMAN sp|P17023-2|ZNF19_HUMAN sp|P17023-2|ZNF19_HUMAN sp|P17023-2|ZNF19_HUMAN
Peptide Sequence
CTFSATGCPSEQPTCLWFR
SFLTALVSLLSVYVTGVCVAFILLSK
QTGGGTTLVVR
VTSNDSAIYICGIAFPSVPEAR
VTSNDSAIYICGIAFPSVPEAR
ENQVSLTVNR
LFPDAIR
YGNDQIPLAPNTGR
SLFLLYALK
SLFLLYALK
LLLTLTEEEFSK
ALGVKPPQNLWEYK
YGNDQIPLAPNTGR
FEDIQQNNDIVQSLAAFQK
FEDIQQNNDIVQSLAAFQK
ETNVLDDEIDSYFK
TIITTNPDIPEANILLNFIR
VCSSYEVDTK
ESINLSTIVDVYTVEQLK
TIITTNPDIPEANILLNFIR
VGALDASPVDLK
EILINVGGR
SPSAFGVIVSFLAAGK
LRPGLAVLGADER
VGGEGTGFGVGGALR
EAVAVDVAVPK
EYGCCPGASTVTWTLR
MTCPLCR
VFCGHEHTLSNLEFAQK
VIPVLEDNYMYLVIEELTR
LSCDFSGLSLTSATLK
GQHAMQFPAELTR
VYNIYIR
EFWLLGHAEIK
EFWLLGHAEIK
GPEPAKPPEPGKPPGPAK
EGSGGSGGSAGLLQQILSLK
AFVGNSPLLR
IHTGERPYQCEECGR
DVETNIDSESTLIQGISEER

WG1. Unkown proteins results. In detail

WG1. Unkown proteins results. In detail

WG1. Unkown proteins results. In detail

WG1. Unkown proteins results. In detail

WG1. Unkown proteins results. In detail

•
•
•
•
•

•
•
•